Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 16741700 | HLA-DR (HLA-DR) | septic shock | NA | NA | NA | positive+negation | |
| 93 consecutive patients with septic shock.measurements and at days 1-2, mhla-dr values (determined by flow cytometry) were not significantly different between survivors and non-survivors. | |||||||
| 16741700 | HLA-DR (HLA-DR) | septic shock | NA | NA | NA | unclassified | |
| the present preliminary results show that mhla-dr is an independent predictor of mortality in septic shock patients. | |||||||
| 17056586 | HLA-DR (HLA-DR) | septic shock | NA | NA | NA | negative | |
| we therefore investigated whether treg could be involved in the decreased monocyte expression of cd14 and hla-dr observed during septic shock. | |||||||
| 19590022 | HLA-DR (HLA-DR) | septic shock | NA | NA | NA | unclassified | |
| in a prospective, randomized, double-blind, placebo-controlled, multicenter trial, 38 patients (19/group) with severe sepsis or septic shock and sepsis-associated immunosuppression (monocytic hla-dr [mhla-dr] <8,000 monoclonal antibodies (mab) per cell for 2 d) were treated with gm-csf (4 microg/kg/d) or placebo for 8 days. | |||||||
| 19590022 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| in a prospective, randomized, double-blind, placebo-controlled, multicenter trial, 38 patients (19/group) with severe sepsis or septic shock and sepsis-associated immunosuppression (monocytic hla-dr [mhla-dr] <8,000 monoclonal antibodies (mab) per cell for 2 d) were treated with gm-csf (4 microg/kg/d) or placebo for 8 days. | |||||||
| 19604380 | HLA-DR (HLA-DR) | septic shock | NA | NA | NA | unclassified | |
| in a prospective observational analysis, 16 consecutive patients with severe sepsis and septic shock (age 59.2 +/- 9.7 years, 13 male, sequential organ failure assessment score 6.1 +/- 2.7) and immunoparalysis (monocytic hla-dr expression < 5,000 antibodies/cell) and 16 healthy volunteers were included. | |||||||
| 19604380 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| in a prospective observational analysis, 16 consecutive patients with severe sepsis and septic shock (age 59.2 +/- 9.7 years, 13 male, sequential organ failure assessment score 6.1 +/- 2.7) and immunoparalysis (monocytic hla-dr expression < 5,000 antibodies/cell) and 16 healthy volunteers were included. | |||||||
| 21805160 | HLA-DR (HLA-DR) | septic shock | NA | NA | NA | negative | |
| hla-dr expression was decreased in both mdcs and pdcs within the septic shock group as compared to healthy controls. | |||||||
| 22701553 | HLA (HLA) | septic shock | NA | NA | NA | unclassified | |
| a multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and hla genotype. | |||||||
| 22701553 | HLA (HLA) | severe sepsis | NA | NA | NA | unclassified | |
| a multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and hla genotype. | |||||||
Copyright 2024